Your search for ‘Smart & Biggar’ returned 2,497 results

2017 has been a banner year for IP litigation in Canada.

The federal government has been proactive in seeking help from industry in tackling the pandemic. For example, Health Canada contacted Health Product Licence Holders to let them know specific...

As discussed in the first part of our article, the Courts have been proactive in ensuring that they keep functioning and allow litigation to proceed during the COVID-19

In Canada, it is difficult to get punitive damages for breach of contract. Awards are uncommon and the amount will usually be relatively small.

On January 29, 2021, the Alberta Court of Appeal dismissed Allergan's appeal of a judicial review decision relating to the interchangeability of its glaucoma drug LUMIGAN RC (0.01% bimatoprost)...

While scheduled to come into force on January 1, 2021 (see here), in recognition

Biotechnology companies have a long road to commercialization. Investors, shareholders and company officials often have their patience tested

On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report. Highlights from 2022-2023 include...

On June 19, 2025, Canada's Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.

On April 15, 2025, Canada's Drug Agency (CDA) released its new five-year strategic plan, Insight to Impact 2025-2030. Formerly the Canadian Agency for Drugs and Technologies in Health (CADTH), this is the CDA's first strategic plan.

On May 20, 2022, the Competition Bureau announced that it closed two investigations into pharmaceutical patent litigation settlement agreements as evidence gathered...

The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence recently published an overview of Project Orbis

As part of Health Canada's initiative to update its approach to regulating self-care products, including non-prescription drugs (broadly, also including cosmetics and natural health products)...

On October 14, 2026, the Patented Medicine Prices Review Board (PMPRB) published the 10th edition of its annual Meds Entry Watch report. The report looks at drug approvals in 2021-2025 by Health Canada, the United States FDA and the European Medicines Agency, as well as sales information on these drugs in Q4 2024.

Health Canada recently published two guidance documents, effective May 23, 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs).

On January 2, 2018, Ad Standards began reviewing and issuing approval numbers for ads for medical devices that comply with Guidelines for Consumer Advertising of Health Products released on December 13, 2017.

PMNOC Proceedings.

On January 29, 2026, the Minister of Health announced Anie Perrault, former Vice-Chairperson, as Chairperson of the Patented Medicine Prices Review Board (PMPRB) until August 9, 2028.